Goldman Sachs’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Goldman Sachs’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,616	Closed	-$95K	–	6839
2021 Q3	$95K	Sell	30,616 -20,681	-40%	-$69K	﹤0.01%	5926
2021 Q2	$191K	Buy	51,297 +38,289	+294%	+$127K	﹤0.01%	5757
2021 Q1	$45K	Buy	13,008 +2,529	+24%	+$10.3K	﹤0.01%	5953
2020 Q4	$35K	Sell	10,479 -3,427	-25%	-$12.3K	﹤0.01%	5413
2020 Q3	$49K	Sell	13,906 -14,611	-51%	-$58.9K	﹤0.01%	5195
2020 Q2	$131K	Sell	28,517 -19,821	-41%	-$87.8K	﹤0.01%	4920
2020 Q1	$160K	Sell	48,338 -68,075	-58%	-$312K	﹤0.01%	4781
2019 Q4	$711K	Buy	116,413 +6,614	+6%	+$27.2K	﹤0.01%	4321
2019 Q3	$458K	Buy	+109,799	New	+$876K	﹤0.01%	4495

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs's PHAS Position: Q4 2021 in Review

Goldman Sachs sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 30,616 shares — an estimated $95K sold.

Goldman Sachs first reported a position in PHAS in Q3 2019 and held it in 9 quarters. The position peaked at $711K in Q4 2019. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

Goldman Sachs reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 30,616 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $95K.
Goldman Sachs first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
Goldman Sachs's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $711K in Q4 2019.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.